Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

bioAffinity Technologies (BIAF) Accumulated Depreciation & Amortization (2021 - 2026)

bioAffinity Technologies has reported Accumulated Depreciation & Amortization over the past 6 years, most recently at $705982.0 for Q1 2026.

  • Quarterly Accumulated Depreciation & Amortization rose 21.72% to $705982.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $705982.0 through Mar 2026, up 21.72% year-over-year, with the annual reading at $704246.0 for FY2025, 31.33% up from the prior year.
  • Accumulated Depreciation & Amortization was $705982.0 for Q1 2026 at bioAffinity Technologies, roughly flat from $704246.0 in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $705982.0 in Q1 2026 and troughed at $2900.0 in Q3 2022.
  • The 5-year median for Accumulated Depreciation & Amortization is $452974.0 (2024), against an average of $450752.3.
  • Year-over-year, Accumulated Depreciation & Amortization rose 3.93% in 2022 and then soared 11484.83% in 2023.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $269180.0 in 2022, then surged by 38.61% to $373123.0 in 2023, then soared by 43.72% to $536251.0 in 2024, then surged by 31.33% to $704246.0 in 2025, then increased by 0.25% to $705982.0 in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Accumulated Depreciation & Amortization are $705982.0 (Q1 2026), $704246.0 (Q4 2025), and $666717.0 (Q3 2025).